An Independent Member of the Blue Shield Association



Qdolo (tramadol, oral solution)

Diagnoses Considered for Coverage:

Moderate to Severe Pain

Coverage Criteria:

For diagnosis of cancer or terminal condition:

- Dose does not exceed 80 ml/day, and
- For cancer pain only: Being prescribed by an Oncologist.

Coverage Duration: one year

For diagnosis of non-cancer moderate to severe pain:

For requests up to 14 day supply

- Dose does not exceed FDA label maximum, and
- Intolerance or contraindication (e.g. inability to swallow tablet) to tramadol IR tablet not expected with Qdolo.

Coverage Duration: up to 14 days

For requests exceeding initial 14 day supply

- Dose does not exceed FDA label maximum, and
- Intolerance or contraindication (e.g. inability to swallow tablet) to tramadol IR tablet not expected with Qdolo, and
- Prescribing or consulting physician attests narcotic quantity requested is necessary to adequately treat acute pain, and
- Not being used in combination with other short-acting narcotics, and
- Anticipated treatment duration is less than 60 days total

Coverage Duration: up to 60 days

For requests for continued use after 14 days

- Prescribing or consulting MD attests narcotic quantity requested is necessary to treat ongoing pain, and
- Provider has documented patient-specific treatment plan for evaluating pain relief, potential misuse, monitoring plan for adverse side effects, and plan to taper opioid use, and
- Not being used in combination with other short-acting narcotics, and
- Dose does not exceed FDA label maximum for up to 3 months

Coverage Duration: 3 months

For requests for continued use after 3 months and yearly thereafter

- Provider has documented patient-specific treatment plan for evaluating pain relief, potential misuse, monitoring plan for adverse side effects, and plan to taper opioid use, and
- Not being used in combination with other short-acting narcotics, and
- Dose does not exceed FDA label maximum

Coverage Duration: up to 1 year

Coverage Duration: see coverage criteria section

Effective Date: 5/3/2023